Glenmark Pharmaceuticals Limited engages in the manufacture and marketing of pharmaceutical formulations and active pharmaceutical ingredients. The company's products include Crofelemer, a Phase III clinical trial product for HIV-related diarrhoea; GRC 8200, which completed Phase IIb clinical trial for the treatment diabetes; GRC 4039 that completed Phase I clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, rheumatoid arthritis, and inflammatory disorders; and GRC 10693, which completed Phase I clinical trial for the treatment of neuropathic pain, osteoarthritis, and other inflammatory pain. The company was incorporated in 1977 and is based in Mumbai.
Legal Address
B/2, Mahalaxmi Chambers,, 22, Bhulabhai Desai Road,
Mumbai; Maharashtra;
Postal Code: 400026
Contact Details: Purchase the Glenmark Pharmaceuticals Ltd. report to view the information.
Website: http://www.glenmarkpharma.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS service
To view more information, Request a demonstration of the EMIS service